Last updated: May 25, 2026
Brigatinib supply is concentrated among large global generics and CDMO networks for bulk drug substance (API) and oral solid dose manufacturing. Downstream capacity for brigatinib tablets is typically served by a small set of CDMOs and API specialists supporting multiple labelers across jurisdictions, with parallel filing, regulatory, and quality packages driving qualification timelines.
What companies supply brigatinib API (bulk drug substance)?
Brigatinib is produced through multi-step chemical synthesis and sold as a controlled small-molecule API to branded and generic manufacturers. Typical supplier categories include:
- API manufacturers that file Drug Master Files (DMFs) or support Abbreviated New Drug Applications (ANDAs).
- Contract API manufacturers (CMOs) that provide brigatinib under supply agreements.
- Tollers that run validated routes for specific particle size, polymorph, and impurity profiles required for finished product equivalence.
Market practice: API sourcing for brigatinib is often structured as (1) pre-qualified supplier qualification for ANDA/505(b)(2) development and (2) continuous supply contracts once analytical comparability and stability data are accepted by regulators and customers.
How are brigatinib API quality specifications set for tablets?
Key quality attributes that drive supplier qualification for oral solids include:
- Impurity profile limits and identification of process-related impurities
- Polymorph form control and habit/particle size distribution
- Water content (relevant for storage stability)
- Residual solvents and heavy metals
- Particle size and flow properties affecting tableting performance
Which companies supply brigatinib tablets (finished dosage forms)?
Finished brigatinib tablets are supplied by branded and generic manufacturers that run validated oral solid dose lines, or by CDMOs that package and tablet under customer-specific specs. Contract manufacturing commonly covers:
- Tablet compression and coating for dose uniformity
- Blister or bottle packaging as per labeling requirements
- Stability program execution (ICH zones)
- Release testing and documentation for regulatory submission
Where does finished dose manufacturing typically happen (US/EU/Asia)?
Brigatinib finished dose supply chains usually split by regulatory and logistics strategy:
- US-focused labelers prioritize US and EU-qualified quality systems for faster post-approval changes.
- EU-focused labelers align with EU GMP Annexes and QP release norms.
- Asia-based manufacturing is used where customers can support bridging data and regulatory acceptance of the manufacturing site and quality management system.
What CDMOs support brigatinib formulation and manufacturing?
CDMOs support brigatinib tablets by handling:
- Formulation transfer (excipients, coating, disintegration and dissolution targets)
- Process development and scale-up
- Manufacturing execution under cGMP
- Analytical methods transfer for potency, impurities, and dissolution
Practical sourcing logic: CDMOs are chosen based on their oral solid dose capacity, experience with high-potency APIs (containment), and speed to complete method transfer and engineering batches.
How do brigatinib supplier qualification and regulatory submissions work?
Supplier qualification is usually gated by regulatory and quality artifacts that connect to the ANDA or 505(b)(2) dossier. Typical steps include:
- API supplier onboarding: DMF reference, CoA capability, impurity spec alignment
- Finished dose characterization: dissolution bridge, stability plan, and analytical method fit
- GMP compliance checks: inspection history, QMS, and data integrity practices
- Change control: post-approval comparability obligations if sourcing shifts
What does “DMF-backed” brigatinib supply mean?
A “DMF-backed” supply model means the API manufacturer’s detailed chemistry, process, specs, and control strategy are submitted to FDA (via DMF) and referenced by downstream applicants. This can reduce rework for method development and improve review efficiency.
What risks exist when switching brigatinib suppliers?
Switching API or finished dose suppliers can trigger:
- Validation gaps for impurities, particle size, or polymorphic form
- Dissolution and bioavailability drift risk from excipient or process changes
- Extended stability periods needed to support regulatory commitments
- Increased cost and timeline due to comparability protocols
How many brigatinib suppliers are active globally?
Active brigatinib supply is constrained by:
- Synthetic route complexity
- High-potency handling requirements
- Regulatory burden for ANDA and NDA manufacturing site qualifications
- Stability and impurity control needs
The effective supplier set for a specific dose strength and packaging configuration is smaller than the number of API/CODMOs operating in the market.
What is the commercial impact of brigatinib supplier concentration?
Supplier concentration affects:
- Lead times for API and finished dose
- Price volatility for small-molecule high-value oncology drugs
- Risk of shortages during qualification transitions
- Bargaining power in supply agreements
How does brigatinib exclusivity affect supplier ramp-up?
Before generic entry, suppliers may limit capacity investment because demand visibility is constrained by exclusivity and litigation timelines. After the first approved generic(s), suppliers typically ramp:
- API capacity expansions aligned to customer firm forecasts
- Finished dose slots reserved for validated tablet lines
- Additional QC capacity for increased batch throughput
What generic entry scenarios change brigatinib sourcing?
If multiple ANDA entrants obtain approvals, labelers often diversify suppliers to reduce single-site risk. This can lead to:
- Multiple API sources for the same ANDA applicant
- Secondary CDMO use for surge capacity
- Safety stock strategies during regulatory change control
Key Takeaways
- Brigatinib supply is handled through a limited set of qualified API makers and oral solid dose manufacturers/CDMOs with strong containment, impurity control, and dissolution performance capability.
- Supplier qualification is dossier-linked: DMF/API specs and finished dose comparability determine regulatory pace.
- Switching suppliers increases validation and regulatory work, especially around impurities, polymorph/particle size, and dissolution.
FAQs
- Do brigatinib APIs require DMF referencing for FDA submissions?
- Which manufacturing steps create the most formulation risk for brigatinib tablets?
- What QC tests most strongly determine whether a new brigatinib API batch is acceptable?
- How do CDMOs structure brigatinib oral solid dose tech transfer for ANDA applicants?
- What supply strategy reduces shortage risk for brigatinib tablet production?
References
- U.S. Food and Drug Administration. Drug Master File (DMF) Program. FDA website.
- U.S. FDA. Guidance for Industry: ANDAs: Content and Format of Abbreviated New Drug Applications. FDA website.
- U.S. FDA. Guidance for Industry: Changes to an Approved NDA or ANDA. FDA website.
(No specific named suppliers were provided because supplier-identifying information for brigatinib depends on the exact labeler/ANDA references and Orange Book listings, which are not included in the input.)
